Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals Academic Article Article uri icon


MeSH Major

  • Actinium
  • Alpha Particles
  • Neoplasms
  • Radioimmunotherapy
  • Radiopharmaceuticals


  • Alpha emitting radionuclides are of considerable interest for targeted radioimmunotherapy. Generator supplied 213Bi emitting 8.5 MeV alpha particles with a 45.6 min half-life has been conjugated to a monoclonal antibody (HuM195-CHX-A-DTPA) for targeted therapy of leukemia in a clinical trial. The clinical dose preparation of pharmaceutical formulation by a pair of skilled radiochemists took 25 min, which corresponds, to an overall decay loss of 30% of the initial 213Bi activity eluted from the generator. In order to allow more widespread and practical clinical use of targeted 213Bi alpha particle therapy, we developed a new procedure that is simpler, more rapid and adaptable to a hospital pharmacy. The new 10 min process includes a tandem elution and labeling, and an anion exchange column purification method that can be reproducibly used.

publication date

  • August 14, 2001



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1016/S0969-8043(01)00048-3

PubMed ID

  • 11545498

Additional Document Info

start page

  • 463

end page

  • 70


  • 55


  • 4